Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515677 | 0.82 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL16093587 | 0.81 | ALDH1A1 (0.67) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL14405394 | 0.81 | ALDH1A1 (0.55) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL3589726 | 0.81 | ALDH1A1 (0.55) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL3677898 | 0.80 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL23382244 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL12223728 | 0.78 | ALDH1A1 (0.63) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL1412523 | 0.78 | ALDH1A1 (0.52) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL25984988 | 0.78 | ALDH1A1 (0.52) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL20995354 | 0.77 | ALDH1A1 (0.51) | ALDH1A1LMNAHPGDSMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001909-A1 | Method for Preparing a Peptide With CCK Receptor Modulatory Activity | CRMH HONG KONG INST OF SCIENCE & INNOVATION CHINESE ACADEMY OF SCIENCES (CN) | 2026-01-01 | — | — | US | claimed |
| EP-4662222-A1 | PROCESS FOR THE PREPARATION OF TETRAPEPTIDE FRAGMENT OF LIRAGLUTIDE | Fresenius Kabi Oncology Ltd (IN) | 2025-12-17 | — | — | EP | claimed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4565705-A2 | COMPOSITIONS AND METHODS FOR MODIFYING MULLER GLIAL CELLS | The Johns Hopkins University (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119904695-A | Construction method of macular degeneration classification system and macular degeneration classification system | 北京石油化工学院 | 2025-04-29 | — | — | CN | claimed |
| CN-118530294-B | Aryl diamine immobilized linker, precursor thereof, preparation method and application | 浙江大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119264965-A | Alkylated nanoparticle, preparation method and application thereof | 湖南大学 | 2025-01-07 | — | — | CN | claimed |
| CN-118956754-A | Induced pluripotent stem cell directional differentiation kit and method | 上海昂朴生物科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118852340-A | Preparation method of polypeptide with CCK receptor agonism/antagonism activity | 中国科学院香港创新研究院再生医学与健康创新中心 | 2024-10-29 | — | — | CN | claimed |
| CN-115044274-B | Ceramic particle modified fiber epoxy composite coating and preparation method and application thereof | 宁波科鑫腐蚀控制工程有限公司 | 2023-04-28 | — | — | CN | claimed |
| WO-2022206871-A1 | PREPARATION AND PURIFICATION METHOD FOR ANTIBODY DRUG CONJUGATE INTERMEDIATE | REMEGEN CO., LTD. (CN) | 2022-10-06 | — | — | WO | claimed |
| CN-115044274-A | Ceramic particle modified fiber epoxy composite coating and preparation method and application thereof | 宁波科鑫腐蚀控制工程有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | claimed |
| EP-3797795-A1 | PREPARATION PROCESS OF ANTIBODY DRUG CONJUGATE INTERMEDIATE | RemeGen, Ltd. (CN) | 2021-03-31 | — | — | EP | claimed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | claimed |
| US-20200138968-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE | REMEGEN, LTD. (CN) | 2020-05-07 | — | — | US | claimed |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP. | 2017-08-03 | — | — | US | claimed |
| EP-3114132-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MOTUS THERAPEUTICS, INC. (US) | 2017-01-11 | — | — | EP | claimed |
| WO-2015134567-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RHYTHM PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | ALDH1A1 3744/4885LMNA 1169/4885HPGD 2668/4885 |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885LMNA 1226/4885HPGD 601/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885LMNA 1226/4885HPGD 601/4885 |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885LMNA 1226/4885HPGD 601/4885 |
| US-20200138968-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE | MMAB, BTD, MGAM | ALDH1A1 440/4885LMNA 3244/4885HPGD 3517/4885 |
| US-20260001909-A1 | Method for Preparing a Peptide With CCK Receptor Modulatory Activity | CCKAR, CCKBR, VIP | ALDH1A1 4641/4885LMNA 2515/4885HPGD 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.